![Fig. 4. HLA-G immunoreactivity in primary CLs. / (A) FCCL (patient BL2, original magnification [OM] × 100). (B) FCCL (patient BL1, OM × 160). (C) MZBCL (patient BL5, OM × 100). (D) Large cell CD30−, CD8+, TIA-1+ CTCL (patient TL17, OM × 200). (E) GSS (patient TL135., OM × 100). (F) A giant multinucleated HLA-G+ cell in GSS (OM × 200). (G) Double immunostaining for HLA-G (red) and CD79a (blue-purple) in FCCL (patient BL4, OM × 630). (H) Double immunolabeling of HLA-G (red) and CD3 (blue-purple) in FCCL (patient BL4, OM × 630). (I) HLA-G (red) and CD3 (blue-purple) immunoreactivity in CTCL (patient TL135., OM × 630). (J) Expression of HLA-G (red) and IL-10 (blue-purple) in CTCL, MF (patient TL13, OM × 200). Colocalization of HLA-G/IL-10 creates a mixed violet-purple pigment, as shown also in panel K (patient TL17, OM × 400). (L) Double immunostaining of HLA-G (red) and CD1a (blue-purple) in CTCL (patient TL4, OM × 400).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/99/2/10.1182_blood.v99.2.609/6/h80222020004.jpeg?Expires=1735535948&Signature=I-HPDsLcfzhLumK10GsM8e7zTzOuiVQRX9usTB~3l8g7w-xW4H0eLf7~IG57vFZYIRFvJTvx2kycIVD2Y586RerXtHzCZWm8QXszAiGNtlTMQxzslGIdFgYPLeTwj4x7yWFEFRDdtJCvtdqnj-FuwPTd6yRh6Et4v~dRuXfLTe8FU6XrIdnhG9~Bqck3kq5YqwNiGpRwkZXjv2wRueQfcO5anHMcZsqxDkZHjwW~vXGzGYiP2uJP0OTzMVKYUO46opiPkrgJte-h7~pqUjKHpHnPC5O-~wgv2PN8xViyKtf1xc9mC8rK~1I9~ttFkmIiaJmEhD~de7m6N4UcraJfkw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
HLA-G immunoreactivity in primary CLs.
(A) FCCL (patient BL2, original magnification [OM] × 100). (B) FCCL (patient BL1, OM × 160). (C) MZBCL (patient BL5, OM × 100). (D) Large cell CD30−, CD8+, TIA-1+ CTCL (patient TL17, OM × 200). (E) GSS (patient TL135., OM × 100). (F) A giant multinucleated HLA-G+ cell in GSS (OM × 200). (G) Double immunostaining for HLA-G (red) and CD79a (blue-purple) in FCCL (patient BL4, OM × 630). (H) Double immunolabeling of HLA-G (red) and CD3 (blue-purple) in FCCL (patient BL4, OM × 630). (I) HLA-G (red) and CD3 (blue-purple) immunoreactivity in CTCL (patient TL135., OM × 630). (J) Expression of HLA-G (red) and IL-10 (blue-purple) in CTCL, MF (patient TL13, OM × 200). Colocalization of HLA-G/IL-10 creates a mixed violet-purple pigment, as shown also in panel K (patient TL17, OM × 400). (L) Double immunostaining of HLA-G (red) and CD1a (blue-purple) in CTCL (patient TL4, OM × 400).
